1.Atorvastatin Improves Cardiac Energy Metabolism In Spontaneous Hypertensive Rats And Ameliorates Cardiac Hypertrophy 2.The Plasma Levels Of VWF, NO In Metabolic Syndrome Patients And Their Relationships With Metabolic Disorders

Partâ… Atorvastatin improves cardiac energy metabolism in spontaneous hypertensive rats and ameliorates cardiac hypertrophyObjectiveTo investigate the effect of atorvastatin on the expression of PPARα mRNA and CPT-I mRNA in myocardium, determine the changes in free fatty acid in serum and myocardium and whether the effects on cardiac energy metabolism can ameliorates cardiac hypertrophy.MethodsSHR and WKY were given atorvastatin 50mg·d^-1·kg^-1 body weight by intragastric administration. After 10 weeks, cardiac hypertrophy parameters, free fatty acid in blood serum and cardiac myocyte and expression of PPARα and CPT-I mRNA were investigated.ResultsFree fatty acid in blood serum and cardiac myocyte of SHR were higher than that in WKY(798.2±38.0nmol/L vs 354.7±27.7nmol/L, P<0.01;635.0±77.4 nmol/L vs 245.3± 47.3nmol/L,P<0.01 respectively). The expression of PPARa and CPT-I gene in cardiac myocyte of SHR decreased as compared with those in WKY group(0.285±0.062 vs 0.478± 0.093,P<0.01;0.795±0.139 vs 1.115±0.109, P<0.01 respectively), VWI and TDM of SHR were higher than those of WKY (3.156±0.084g/kg vs 2.990±0.095 g/kg.P<0.05;21.32± 1.25μm vs 18.18±0.75μm,P<0.01 respectively). After 10 weeks of treatmetnt with atorvastatin,free fatty acid in blood serum of ATV group were lower than in SHR group(571.0±40.8 nmol/L vs 798.2±38.0nmol/L,P<0.01), however,still higher than in WKY group(571.0±40.8 nmol/L vs 354.7± 27.7 nmol/L,P<0.01).Free fatty acid in cardiac myocyte were lower in ATV group than in SHR group (287.7±57.7 nmol/L vs 635.0±77.4 nmol/L, P<0.01). The expression of PPARa and CPT-I mRNA in cardiac myocyte of ATV group were higher than those in SHR group (0.457±0.075 vs 0.285±0.043,P<0.01;1.037±0.101, P<0.05 respectively), and similar with those in WKY group(P>0.05). VWI and TDM of ATV group were lower man those of SHR group(2.984±0.049g/kg vs 3.156±0.084g7kg,PO.01;18.91±1.05 pan vs 21.32±125jumyP<0.05), and similar with those in WKY groupConclusionFatty acid oxidation decrease in cardac myocyte of SHR. Atorvastatin may ameliorate cardiac hypertrophy by improves cardiac energy metabolism in the SHR.PartnThe plasma levels of vWF,' NO in metabolic syndrome patients and their relationships with metabolic disordersObjectiveTo investigate the plasma levels of vWF,NO in patients with different amount of metabolic disorders and to study theirs relationships with these disorders. MethodsThe plasma levels of the vWF,NO were examined in metablic syndrome patients(n=36), patients with 1 ² metabolic disorders(n=43) and patients without any metabolic disorders (n=30) as control. ResultsThe plasma vWF level was higher in metabolic syndrome group than in 1² metabolic disorders group(P <0.05),higher in 1² metabolic disorders group than in control group(P <0.05),higher in metabolic syndrome group than control group(P <0.01).The level of NO was lower in metabolic group than control group(P <0.05),lower in 1 ² metabolic disorders group than in control group(P <0.05),the difference between metabolic syndrome and 1 ² metabolic disorders group is not significant(P =0.717).But the difference is significant when comparing the non-DM patients in the two groups( P <0.05).Mulu"ple stepwise regression shows that vWF is correlated to systolic BP(SBP), diastolic BPQDBP) and pulse BP,and that NO is correlated to BMI,SBP and TG. ConclusionMultiple metabolic disorders of metabolic syndrome injure endothelial cell.The degree of endothelial cell injury correlate to the BMI,SBPJ)BP,pulse BPandTG.